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Abstract
Background: There is conflicting evidence on the immunologic benefit of treating helminth co-infections (‘‘deworming’’) in
HIV-infected individuals. Several studies have documented reduced viral load and increased CD4 count in antiretroviral
therapy (ART) naı̈ve individuals after deworming. However, there are a lack of data on the effect of deworming therapy on
CD4 count recovery among HIV-infected persons taking ART.
Methodology/Principal Findings: To estimate the association between empiric deworming therapy and CD4 count after
ART initiation, we performed a retrospective observational study among HIV-infected adults on ART at a publicly operated
HIV clinic in southwestern Uganda. Subjects were assigned as having received deworming if prescribed an anti-helminthic
agent between 7 and 90 days before a CD4 test. To estimate the association between deworming and CD4 count, we fit
multivariable regression models and analyzed predictors of CD4 count, using a time-by-interaction term with receipt or nonreceipt of deworming. From 1998 to 2009, 5,379 subjects on ART attended 21,933 clinic visits at which a CD4 count was
measured. Subjects received deworming prior to 668 (3%) visits. Overall, deworming was not associated with a significant
difference in CD4 count in either the first year on ART (b = 42.8; 95% CI, 22.1 to 87.7) or after the first year of ART (b = 29.9;
95% CI, 224.1 to 4.4). However, in a sub-analysis by gender, during the first year of ART deworming was associated with a
significantly greater rise in CD4 count (b = 63.0; 95% CI, 6.0 to 120.1) in females.
Conclusions/Significance: Empiric deworming of HIV-infected individuals on ART conferred no significant generalized
benefit on subsequent CD4 count recovery. A significant association was observed exclusively in females and during the
initial year on ART. Our findings are consistent with recent studies that failed to demonstrate an immunologic advantage to
empirically deworming ART-naı̈ve individuals, but suggest that certain sub-populations may benefit.
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which helminth infection might impair immunologic control of the
HIV virus and accelerate disease progression. These include
suppression of antiviral Th1 lymphocyte responses by helminthdriven Th2 lymphocyte skewing [4,5], helminth-induced stimulation
of other immunosuppressive cytokine responses [6], potentiation of
cellular susceptibility to viral entry resulting from increased coreceptor expression [7,8], and augmentation of systemic immune
activation [3,5,9,10]. A mechanism whereby helminth infection
increases systemic immune activation is particularly intriguing, given
the growing evidence that systemic inflammation and immune
activation are associated with poor clinical outcomes in HIV-infected
individuals on ART [10,11,12].

Introduction
Despite increased access to antiretroviral therapy (ART) in subSaharan Africa [1], HIV outcomes in this region have lagged behind
those in more industrialized regions [2]. Although a complex interplay
of economic, biologic, and sociobehavioral factors underlies this
discrepancy, one potential contributing factor is the high rate of
endemic, chronic, and overlapping parasitic co-infections, including
schistosomiasis and the three major soil-transmitted helminth (STH)
infections: Ascaris lumbricoides, Trichuris trichiura, and hookworms –
caused by two species, Ancylostoma duodenale and Necator americanus [3]. A number of potential pathways have been proposed by
PLOS Neglected Tropical Diseases | www.plosntds.org
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dysfunctional gastrointestinal mucosal barrier [31,32,33] – is
associated with mortality and adverse clinical outcomes, even
among those achieving viral suppression on ART
[11,34,35,36,37,38]. In response, a number of interventions are
in development and testing which aim to reduce immune
activation in this population [39]. Given the potential associations
between STH infection, disruption of the gut mucosal barrier, and
immune activation, deworming therapy warrants further exploration as such an intervention.
Our primary objective was to estimate the association between
empiric deworming and change in CD4 count over time in HIVinfected individuals receiving ART in southwestern Uganda. We
hypothesized that receipt of deworming therapy (versus no
antecedent deworming) was associated with greater increase in
CD4 count. In the Mbarara district, where the majority of our
study population resides, combined prevalence of the three major
STH infections is estimated to be 20–50% [40,41,42,43,44].
Hookworm is the most commonly identified STH in epidemiologic surveys, both in this district and throughout East Africa
[41,42,43]. Although schistosomal infection is endemic in many
Ugandan communities living around low-lying bodies of fresh
water, it is relatively uncommon in the higher altitude areas of
Mbarara district [45,46]. As a result, our clinic does not routinely
perform diagnostic testing for Schistosoma species or administer
empiric praziquantel.
A secondary objective was to estimate the association between
empiric deworming and other markers of nutritional status, such
as body mass and anemia, during treated HIV infection. Because
STH infection is an important cause of malnutrition – specifically,
hookworms are known to cause gastrointestinal blood loss resulting
in iron deficiency anemia [47] – we hypothesized that deworming
was associated with greater increase in total body mass and blood
hemoglobin concentration with time on ART.

Author Summary
It is estimated that up to half of all people infected with
HIV in sub-Saharan Africa are co-infected with one or more
gastrointestinal parasites. These parasitic infections may
negatively impact the ability of the immune system to
combat the HIV virus, leading to worse clinical outcomes in
people with HIV. Therefore, routine, universal, empiric
treatment of gastrointestinal parasite infections (‘‘deworming’’) has been suggested as one strategy for optimizing
HIV outcomes in this region. Previous studies have
provided conflicting results on whether empiric deworming positively impacts markers of HIV disease progression
such as CD4 count and viral load, but all of these studies
were performed in HIV-infected individuals not yet on
antiretroviral therapy. In this study, we measured the
association between receipt of empiric deworming and
CD4 count over time in HIV-infected adults taking
antiretroviral therapy in southwestern Uganda, an area
with a high parasite burden. We found that, overall, there
was no significant association between deworming and
change in CD4 count; however, when we performed a subanalysis looking exclusively at females during the first year
of ART, deworming was associated with significantly
increased CD4 count. These results suggest that empiric
deworming may not be an effective generalized strategy
for improving HIV treatment outcomes in sub-Saharan
Africa; however, the possibility of targeted benefit in
specific sub-populations deserves further investigation.
The geographic distributions of HIV and STH infection in subSaharan are largely overlapping [13]. Existing anti-helminthic
drugs are well-tolerated, inexpensive, and easy to administer
[14,15]. On the other hand, barriers to diagnosing STH infection
in resource-constrained settings are considerable [16], given that the
current gold standard method of stool microscopy is both labor
intensive and lacks optimal sensitivity [17,18,19,20]. Furthermore,
chronic gastrointestinal STH carriage is frequently asymptomic, or
presents only with vague and non-specific manifestations that are
common among HIV-infected persons – such as weight loss,
nutritional deficiency, anemia, abdominal discomfort, or diarrhea
[21,22]. Therefore, routine empiric treatment of STH infection
(‘‘deworming’’) in HIV-infected individuals living in regions with
high prevalence of STH has been suggested as a potential
intervention to delay HIV disease progression in ART naı̈ve
patients [4,22,23]. Studies testing this hypothesis in ART-naı̈ve
populations have been conflicting [24,25,26,27]. A meta-analysis
compiling data from three randomized controlled trials demonstrated a significantly lower plasma viral load and higher CD4 count
in individuals receiving definitive therapy for confirmed helminth
infection [28]. However, a more recent multi-site randomized
controlled trial, reported by Walson and colleagues, demonstrated
no beneficial impact of empiric deworming on markers of HIV
disease progression in a similar ART-naı̈ve population [29].
Most prior studies investigating the impact of empiric deworming on markers of HIV disease progression have been performed
in ART-naı̈ve individuals. There is a paucity of data to
demonstrate the impact of deworming on clinical outcomes
among HIV-infected persons taking ART. In the past decade
over 8 million people living with HIV/AIDS have gained access to
ART [1] and this number is expected to continue to grow rapidly
as international guidelines recommend earlier treatment at higher
CD4 counts [30]. There is increasing evidence that persistent
immune activation – perhaps mediated to some extent by the
translocation of pro-inflammatory microbial products across a
PLOS Neglected Tropical Diseases | www.plosntds.org

Methods
Ethics statement
Ethical approval for all study procedures was obtained from the
Committee on Human Research, University of California at San
Francisco; the Partners Human Research Committee, Massachusetts General Hospital; and the Institutional Review Committee,
Mbarara University of Science and Technology. Consistent with
national guidelines, we received clearance for the study from the
Uganda National Council for Science and Technology and from
the Research Secretariat in the Office of the President. The
database used for this analysis is primarily a clinical database.
Personal identifiers and protected health information are removed
prior to data extraction and analysis. As such, all ethical review
committees granted a waiver for informed consent.

Study design and population
We conducted a retrospective, observational study among HIVinfected adults on ART at a large, publicly operated, regional HIV
clinic located on the campus of the Mbarara Regional Referral
Hospital in southwestern Uganda. Clinical data from 1998
through 2009 were analyzed in this study. Depending on clinical
status, patients were seen in the clinic approximately two to six
times annually. We included all subjects aged 17 years or greater
who were on ART and had at least one recorded CD4 count test
during the study period.

Definition of variables
For a given CD4 count measurement, subjects were assigned as
having received deworming treatment if they were prescribed
2
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greater than 90 days, and that some subjects who received
deworming may have simply not been scheduled for a CD4 count
measurement within the 7 to 90 day time window after
deworming. Therefore, we performed analyses in which credit
for deworming was extended to CD4 count measurements up 120
days and 180 days after treatment. Finally, although several
compelling socio-demographic indicators were missing for the
majority of our subjects, we performed a sensitivity analysis in
which educational attainment, monthly income, and travel time
from home to clinic were added as co-variables to our primary
model in a step-wise fashion. For our secondary analyses, we
performed sensitivity analyses in which we extended credit for
deworming up to 120 and 180 days, stratified by gender, and
excluded outliers, defined as body mass or hemoglobin measurements that were +/23 standard deviations from the median. All
data analysis was performed using Stata version 11.2 (StataCorp,
College Station, Texas).

either albendazole or mebendazole between 7 and 90 days before
the date of the CD4 test. The same 7 to 90 day time window was
used to assign credit for deworming with respect to the date of
measurement for our secondary outcomes, body mass and
hemoglobin. Standard practice in this clinic was to administer a
single oral dose of either albendazole (500 milligrams) or
mebendazole (400 milligrams) for routine deworming approximately once per year (which corresponds to approximately every
six visits). We chose a 7 to 90 day window to assign credit for
having received deworming therapy based on evidence that the
likelihood of STH re-infection approaches 50% at 90 days posttreatment [48]. Additionally, this time window was chosen in
order to maintain consistency with prior studies that examined the
effect of deworming on CD4 count at 70 to 112 days after
deworming [24,25,26,27].

Statistical analysis
We compared baseline characteristics between subjects who
received at least one deworming treatment and those who received
no deworming during the study period. Categorical variables were
compared between these groups using chi squared testing, and
continuous variables using the equality of medians test.
In our primary analysis, we fit a multivariable linear regression
model to estimate the association between deworming and CD4
count. The primary explanatory variables of interest were time on
ART, receipt (vs. non-receipt) of deworming, and an interaction
between these two variables. Because graphical depiction of CD4
changes on ART demonstrated a clear leveling of the rate of
increase in CD4 count after one year of ART, we implemented a
linear spline model for duration of ART with a knot at one year.
We then carried out a sub-analysis stratified by gender, to
determine if there was a differential effect of deworming in males
versus females. Finally, we performed two secondary analyses to
estimate the association between deworming and 1) body mass
(kilograms), and 2) blood hemoglobin concentration (grams per
deciliter). We fit a separate multivariable linear regression model
for each of these secondary outcomes, similarly using time on
ART, receipt (vs. non-receipt) of deworming, and a time by
deworming interaction term as our explanatory variables of
interest.
To account for within-participant clustering over time, we used
cluster-correlated robust estimates of variance [49,50]. We
adjusted for known correlates of HIV disease progression and
CD4 count change, including age, time on ART, co-morbid
tuberculosis infection, and pregnancy (if applicable). We considered also adjusting for known socio-demographic predictors of
STH infection, such as educational attainment, socioeconomic
status, and rural (versus urban) residence [18,51]; however, in our
clinical database these variables were inconsistently documented
over the course of the study period. Given the high degree of
missing data and the uneven distribution of missingness with
respect to other subject characteristics, we did not include these
additional co-variables in our final analyses. However, we did
employ the following relevant variables in a sensitivity analysis:
educational attainment, monthly income, and travel time from
home to clinic.
To test the robustness of our primary model, we performed
several sensitivity analyses. First, we fit a model in which CD4
count outliers were excluded. Outliers were defined as CD4 count
measurements that varied by greater than 400 cells/mm3
(approximately +/22 standard deviations from the median
change in CD4 count) from the immediately previous or
subsequent measurement. Additionally, we considered that the
potential benefit of deworming on CD4 count may persist for
PLOS Neglected Tropical Diseases | www.plosntds.org

Results
From 1998–2009, a total of 5,379 subjects on ART attended
21,933 clinic visits at which a CD4 count was measured. Sixty-one
percent of subjects were female. The median baseline CD4 count
and age at the time of ART initiation were 270 cells/mm3 and
38.3 years, respectively. During our study period, the median
number of clinic visits per subject at which a CD4 count was
measured was four. A total of 2,781 out of 5,379 (52%) subjects
received deworming therapy at least once during the observation
period, and a total of 668 (3%) CD4 count measurements were
preceded by deworming therapy within the 7 to 90 day time
window. Baseline characteristics, compared between subjects that
received deworming therapy at least one time during the study
period and those that received no deworming therapy during the
study period, are summarized in Table 1.
In our primary multivariable linear regression analysis
(Table 2), deworming was not significantly associated with a
change in CD4 count over time in either the first year on ART
(b = 42.8; 95% CI, 22.1 to 87.7) or after the first year of ART
(b = 29.9; 95% CI, 224.1 to 4.4). In this model, statistically
significant predictors of CD4 count were age, time on ART,
tuberculosis co-infection, and receipt of deworming. Based on
estimates derived from our primary model, predicted CD4 count
as a function of time on ART is graphically depicted in Figure 1.
In our sensitivity analyses, excluding outlier CD4 values, extending
the treatment window, or adjusting for additional socio-demographic variables did not yield qualitatively different results.
In the sub-analysis restricted to female gender (Table 3),
deworming was significantly associated with a greater increase in
CD4 count during the first year of ART (b = 63.0; 95% CI, 6.0 to
120.1), but not after the first year of ART (b = 215.4; 95% CI,
232.6 to 1.8). Statistically significant predictors of CD4 count
were time on ART, tuberculosis co-infection, pregnancy, and
receipt of deworming. When the analysis was restricted to male
gender, deworming was not significantly associated with CD4
count change in either the first year on ART (b = 13.0; 95% CI,
257.4 to 83.4) or after the first year of ART (b = 26.9; 95% CI,
229.3 to 15.5). Statistically significant predictors of CD4 count for
males were time on ART and tuberculosis co-infection. Notably,
as compared to males in our study population, females were
significantly younger (median age 36.2 vs. 41.3; p,0.001), more
likely to have initiated ART after 2007 (48.1% vs. 44.4%;
p = 0.009), less likely to have ever had tuberculosis during the
study period (15.2% vs. 25.6%; p,0.001), and had significantly
higher pre-ART baseline CD4 count (282 vs. 248; p,0.001).
3
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Table 1. Subject characteristics.

Characteristic
Gender; n (%)

n

Received deworming at
least once during study
period (n = 2781)

Never received deworming
during study period
(n = 2598)

x2 (p-value)

0.47 (0.50)

5379

Female

3302

1695 (61.0%)

1607 (61.9%)

Male

2077

1086 (39.0%)

991 (38.1%)

Time of ART initiation; n (%)

5379

Prior to January 1, 2007

2868

1482 (53.3%)

1386 (53.4%)

On or after January 1, 2007

2511

1299 (46.7%)

1212 (46.6%)

Baseline CD4 count at time of ART initiation;
median (IQR)

5379

265 (163–392)

273 (166–395)

1.72 (0.19)

Age at time of first post-ART CD4 count
(years); median (IQR)

5359

38.4 (32.5–44.3)

38.0 (32.4–44.7)

1.42 (0.23)

Clinic visits at which CD4 count was obtained;
median (IQR)

5379

4 (2–6)

3 (2–5)

90.49 (,0.001)

0.77 (0.38)

Education; n (%)

2106

Primary only

1457

847 (69.9%)

610 (68.2%)

Secondary or greater

649

364 (30.1%)

285 (31.8%)

Monthly income (Uganda shillings)*; n (%)

1439

,100000

1095

616 (76.1%)

479 (76.0%)

$100000

344

193 (23.9%)

151 (24.0%)

Self-reported travel time from home to clinic

0.002 (0.96)

1577

,1 hour

815

464 (52.6%)

351 (50.5%)

.1 hour

762

418 (47.4%)

344 (49.5%)

1033

540 (19.4%)

493 (90.0%)

4346

2241 (80.6%)

2105 (81.0%)

Diagnosed with TB at least once during study
period
Yes
No
Pregnant at least once during study period

0.002 (0.97)

0.69 (0.41)

5379
0.17 (0.68)

3302

Yes

733

375 (22.1%)

358 (22.3%)

No

2569

1320 (77.9%)

1249 (77.7%)

0.01 (0.92)

*100000 Uganda shillings valued at approximately 40 USD as of April 1, 2014.
doi:10.1371/journal.pntd.0003036.t001

Table 2. Primary analysis: multivariable linear regression model of predictors of CD4 count (n = 5379).

Parameter

b

95% CI

p-value

Time on ART
0 to 1 year (per year of ART up to 1 year)

98.5

85.5 to 111.6

,0.001

.1 year (per year of ART after 1 year)

31.2

26.8 to 35.6

,0.001

Age (each year of age)

20.8

21.4 to 20.2

0.011

TB co-infection

2114.8

2153.9 to 275.8

,0.001

Deworming

255.6

286.3 to 225.0

,0.001

0 to 1 year on ART

42.8

22.2 to 87.7

0.062

.1 year on ART

29.9

224.1 to 4.4

0.174

Deworming6Time on ART interaction term{

{

Predicted difference in CD4 count between patients receiving versus not receiving deworming therapy in the past 90 days. The interaction terms were separated by
duration of prior ART use as up to 1 year of therapy versus greater than 1 year of therapy.
doi:10.1371/journal.pntd.0003036.t002

PLOS Neglected Tropical Diseases | www.plosntds.org
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Figure 1. Predicted CD4 count by time on ART. Predicted values are based on the multivariable linear regression model y = a+b1t+b2t+b3t+b4t,
where the independent variable, y, is CD4 count; the dependent variable, t, is time on ART, the y-intercept, a, is CD4 count at t = 0, and b1–b4 are
respective b-coefficients for the co-variables age, TB co-infection, deworming, and deworming*time interaction.
doi:10.1371/journal.pntd.0003036.g001

95% CI, 0.04 to 0.25) time windows. Otherwise, the remaining
sensitivity analyses for both the body mass and hemoglobin
outcomes yielded qualitatively similar results to the original
models.

Females and males were not significantly different with respect to
the likelihood of receiving deworming at least once during the
study period, as well as the median number post-ART visits at
which a CD4 measurement was obtained.
In the secondary analyses, there was no significant effect of
deworming on either body mass (b = 20.09; 95% CI, 20.40 to
0.23) or hemoglobin (b = 0.08; 95% CI, 20.05 to 0.22) over time
(Table 4). Statistically significant predictors of both body mass and
hemoglobin were time on ART, age, tuberculosis co-infection, and
receipt of deworming. The sensitivity analysis in which we
extended the time window for assigning deworming credit and
simultaneously restricted the population to females resulted in the
new observation that deworming was significantly associated with
increased hemoglobin concentration over time for both the 120
day (b = 0.15; 95% CI, 0.02 to 0.27) and the 180 day (b = 0.14;

Discussion
In this retrospective analysis accounting for over 600 deworming events in more than 5,000 persons accessing HIV care at a
public clinic during a 10 year period in rural Uganda, we found no
generalized benefit of empiric deworming on CD4 count recovery
among HIV-infected individuals on ART. Although it did not
reach statistical significance, it is notable that deworming predicted
an increased CD4 count over time during the first year on ART,
but not during subsequent years. Additionally, in the sub-

Table 3. Multivariable linear regression model of predictors of CD4 count, stratified by gender (n = 5379).

Female (n = 3302)
Parameter

b

Male (n = 2077)
95% CI

p-value

95% CI

b

p-value

Time on ART
0 to 1 year (per year of ART up to 1 year)

109.8

92.5 to 127.0

,0.001

65.6

45.2 to 86.0

,0.001

.1 year (per year of ART after 1 year)

38.4

32.1 to 44.7

,0.001

22.6

16.9 to 28.4

,0.001

Age

0.1

20.8 to 1.0

0.777

0.3

20.6 to 1.1

0.578

TB co-infection

2104.4

2161.3 to 247.4

,0.001

2109.5

2159.0 to 260.1

,0.001

Pregnant

231.8

253.1 to 210.7

0.003

n/a

n/a

n/a

Deworming

267.3

2103.9 to 230.7

,0.001

234.3

288.7 to 20.1

0.217

Deworming during 0 to 1 year on ART

63.0

6.0 to 120.1

0.030

13.0

257.4 to 83.4

0.717

Deworming during .1 year on ART

215.4

232.6 to 1.8

0.078

26.9

229.3 to 15.5

0.544

Deworming6Time on ART interaction{

{
Predicted difference in CD4 count between patients receiving versus not receiving deworming therapy in the past 90 days. The interaction terms were separated by
duration of prior ART use as up to 1 year of therapy versus greater than 1 year of therapy.
doi:10.1371/journal.pntd.0003036.t003

PLOS Neglected Tropical Diseases | www.plosntds.org
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Table 4. Secondary analysis: multivariable linear regression modeling of predictors of body mass and blood hemoglobin
concentration.

Parameter

b

95% CI

p-value

Body Mass (kg), n = 7225
Time on ART (years)

1.11

0.97 to 1.25

,0.001

Age (each year of age)

0.08

0.05 to 0.11

,0.001

TB co-infection

24.95

25.88 to 24.03

,0.001

Deworming

22.43

22.99 to 21.87

,0.001

Deworming6Time on ART interaction term{

20.09

20.40 to 0.23

0.599

Hemoglobin (g/dl), n = 4811
Time on ART (years)

0.33

0.30 to 0.37

,0.001

Age (each year of age)

0.01

0.00 to 0.02

0.001

TB co-infection

21.67

22.37 to 20.97

,0.001

Deworming

20.81

21.15 to 20.47

,0.001

Deworming6Time on ART interaction term{

0.08

20.05 to 0.22

0.222

{

Predicted difference in body mass or blood hemoglobin concentration between patients receiving versus not receiving deworming therapy in the past 90 days.
doi:10.1371/journal.pntd.0003036.t004

population of females, deworming predicted a significantly greater
rise in CD4 count during the first year on ART. Not only was the
latter effect statistically significant, but compared to our primary
model the magnitude of CD4 count increase was greater. In the
secondary analysis, deworming conferred no benefit on body
weight over time. Similarly, in our original model for the
hemoglobin outcome, deworming conferred no benefit on
hemoglobin level over time; however, we did observe a small
but significant increase in hemoglobin level with deworming when
we concurrently restricted the population to females and extended
the time window for assigning deworming credit to 120 or 180
days before a given hemoglobin measurement.
Interestingly, in both our primary model and the sub-analysis
restricted to females, baseline CD4 count at time of ART initiation
was significantly lower in subjects who received deworming. One
possible explanation for this would be if clinicians were more likely
to recommend deworming to patients who were judged to be
clinically more ill, or more specifically to those with lower CD4
counts. This notion is supported by our finding that both baseline
body weight and hemoglobin were also lower in subjects who
received deworming. Given that we observed a non-significant
trend toward greater CD4 count recovery during the first year of
ART with deworming (and a significant effect in the female subanalysis), it is intriguing to speculate that our estimate did not
reach significance simply due to methodological limitations, such
as an unidentified bias toward the null, under-powering, or
residual confounding. Additionally, the dominant effect of ART
on CD4 count recovery may have masked any smaller, but still
potentially significant, effect of deworming. In light of these
limitations, it is critical to interpret the above findings in the
context of the disparity in baseline CD4 count between those
receiving deworming and those not (Table 1). The fact that,
independent of deworming, there was no significant association
between baseline CD4 count and rate of CD4 count rise during
the first year of ART (data not shown) suggests that a true
treatment effect may be more likely.
It should be noted that females in our study population differed
significantly from males with respect to several important baseline
characteristics in our model, including age, tuberculosis coinfection, and baseline CD4 count. Our finding that deworming
PLOS Neglected Tropical Diseases | www.plosntds.org

had a significant benefit for females during the first year on ART
may be partly explained by the fact that females in our population
were younger and less likely to have tuberculosis co-infection, since
both age and tuberculosis co-infection were inversely associated
with CD4 count in our primary model, and in prior studies
[52,53]. Notably, our models included both age and tuberculosis
co-infection, which should account for potential confounding by
these factors.
We are unaware of prior data supporting a differential impact of
deworming between males and females. The most likely explanation is unmeasured confounding between these two groups.
Barring that, a plausible explanation for our findings would be
greater prevalence of helminth infection or higher parasite load
among females in our population. However, we have no
compelling reason to suspect this. In fact, several studies in
HIV-infected populations have demonstrated that prevalence of
STH infection in some areas of East Africa is actually similar to or
lower in females than in males [54,55,56,57]. However, that these
studies were conducted in regions outside of our geographic area
of scope and may not be generalizable to our study population.
Models demonstrating the impact of deworming on changes in
body mass and hemoglobin after ART initiation paralleled the
results of our primary analysis of CD4 count. Although both
models failed to demonstrate a significant effect of deworming,
time on ART was strongly associated with both greater body mass
and greater hemoglobin levels. Similarly, tuberculosis co-infection
was strongly associated with both decreased body mass and
decreased hemoglobin level. Taken together, these findings
support the validity of the analyses because they are consistent
with anticipated results based on known relationships.
Interestingly, in a sensitivity analysis in which we permitted an
increased duration of deworming therapeutic response from 90 to
120 or 180 days, we found that deworming was associated with
increases in hemoglobin in females only. This finding may be
explained by the fact that hemoglobin levels are checked less
frequently than CD4 count in our clinical population. Therefore,
lengthening the deworming therapeutic time window may have
increased the number of hemoglobin measurements receiving
credit for deworming, thereby increasing the statistical power to
allow for measurement of this association. Alternatively, it is
6
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possible that a period of time greater than 90 days is required for
deworming to sufficiently exert an effect on hemoglobin levels,
which is consistent with the known red blood cell life span of
approximately 120 days. Alternatively, deworming may confer a
benefit on hemoglobin levels directly by reducing the gastrointestinal parasite load, particularly with respect to hookworms.
Although this study is strengthened by its large sample size
(668 deworming visits) and ability to adjust for key confounding
variables, we acknowledge that there are several notable
limitations beyond the inherent risks for confounding and bias
in a retrospective analysis. First, although STH infection is
reported to be high in southwestern Uganda [40,41,42,43,44],
actual prevalence in our study population was unknown. Lower
rates of infection than previously published would bias the
observed effect of any true deworming treatment effect towards
the null. Similarly, STH infection intensity (stool parasite load)
was also unmeasured, although it should be considered as a
factor that may modulate any potential effect of empiric
deworming. The intensity of STH infection has been shown to
correlate with certain markers of clinical disease severity,
including anemia and eosinophilia [18,19]. Therefore, it is
conceivable that deworming may exert a greater beneficial effect
on CD4 count recovery in the setting of higher intensity STH
infection. Second, because viral load monitoring was not
routinely available in our study setting, it is not possible to
adjust for the presence or absence of viral suppression, an
important predictor of CD4 reconstitution. We would only expect
confounding if receipt of deworming therapy were associated with
virologic failure, which is unlikely given the nearly equivalent
patterns of CD4 reconstitution observed in both groups. Third, a
small incremental effect conferred by deworming may be obscured
by the expected dominant effect of ART (and resulting suppression
of HIV activity) on CD4 count recovery. Fourth, although most
patients (52%) received deworming therapy at least once during the
observation period, deworming therapy was recorded prior to only
3% of visits with a corresponding CD4 count measurement, which
is less than what would be expected with annual deworming visits
(i.e. closer to 10–20%). Fifth, patients at our clinic site receive only a
single dose of either mebendazole or albendazole at each
deworming. Therefore, it is possible that high rates of STH reinfection [48] and incomplete eradication of parasite load with
standard doses of anti-helminthic therapy [58], especially in
individuals with a large parasite burden, may obscure the potential
benefit of deworming on CD4 count recovery.
Finally, host-parasite interactions during STH infection are
complex and incompletely understood. In addition to causing disease,
helminths have been associated with protection from atopic
syndromes and other pathologic inflammatory conditions [59,60].
Like these conditions, untreated HIV infection is characterized by the
presence of exuberant systemic inflammation and immune activation.
This lessens with the initiation of ART, but never completely
normalizes to the levels seen in HIV-uninfected individuals [12,36].
Furthermore, even in the setting of virologic control on ART, higher
levels of immune activation are associated with increased risk for HIV
disease progression and mortality [11,12,33,36]. Given that there are
conflicting data on the association between STH infection and
immune activation [3,5,61,62], it is plausible to consider that STH
infection may promote immune activation only in certain circumstances. This is supported by evidence that STH infections may both
promote and protect against immune activation – by disrupting the
gut mucosal barrier during high-intensity infection, or by reinforcing
mucosal barriers in other settings, respectively [63].
Therefore, we cannot rule out the possibility that, depending on
host and parasite-specific characteristics (for example: helminth
PLOS Neglected Tropical Diseases | www.plosntds.org

species, stage of infection, host genetic factors), STH infection –
and therefore deworming – may alternately confer either
beneficial or deleterious effects on HIV disease progression.
Indeed, it has been suggested that low-intensity infection with
certain helminth species may protect against HIV disease
progression [5,64]. Thus, it is possible that only under certain
circumstances will deworming confer a significant benefit on HIV
disease progression or CD4 count recovery. Under certain
conditions, deworming could even cause harm by disrupting as
yet incompletely understood pathways by which helminths protect
against pathologic inflammation and T-cell activation. Alternatively, anti-helminthic agents could have pleiotropic effects with
either antiviral or immunomodulatory properties.
One might consider a hypothetical model in which deworming
is beneficial during the most active period of STH-mediated
mucosal disruption (such as early in the natural history of STH
infection), but is in fact detrimental or has no effect during chronic,
stable, low-intensity infection – when protective anti-inflammatory
or mucosal barrier stabilizing effects of STH infection presumably
predominate. Consistent with this model, the variation in life cycle
and time course of infection between different STH species may
explain species-specific differences in the effect of deworming on
HIV disease progression that have been observed in certain
settings [24,55]. Furthermore, several studies have demonstrated
an association between STH infection and higher CD4 count in
ART-naı̈ve, HIV-infected individuals [18,51,54]. Although potentially confounded by a number of factors, this finding is
consistent with a model in which low-intensity STH infection
confers a beneficial effect on CD4 count.
In summary, our findings are consistent with previous studies
that failed to find a benefit of empiric deworming in ART-naı̈ve,
HIV-infected individuals [25,29,55], but also suggest that there
may be a modest benefit among women on ART. Although our
study does not support a role for universal, empiric deworming as
a method to improve immune reconstitution in the general
population of HIV-infected persons on ART, this strategy
warrants further investigation as a potential adjunct to optimize
ART effectiveness in females. Regardless of these results,
deworming should continue to be a fundamental part of routine
care for individuals living in areas highly endemic for STH
infection.
Given the inherent constraints of our retrospective study design,
including the inability to select at least a representative sample of
subjects with confirmed and quantified STH infection, there is a
need for more thoroughly controlled, randomized, and prospective
studies that will avoid such limitations. These future investigations
could more clearly establish any deworming treatment effects of
targeted benefit to those with confirmed STH infections. Future
studies should also examine the role of deworming using optimally
effective anti-helminthic drug regimens, the effect of empiric
treatment on specific sub-populations, and the impact of
deworming on other surrogate and clinical markers or sequelae
of HIV disease, including immune activation, systemic inflammation, gut microbial translocation, and cardiovascular disease.
Additional investigations are also warranted to confirm our finding
of improved CD4 count recovery with empiric deworming in the
sub-population of females.
Finally, to our knowledge this is the first study to describe the
impact of deworming on clinical and immunologic markers of
HIV disease in patients on ART. Given the increasing accessibility
of ART in sub-Saharan Africa and other regions that are coendemic for HIV and STH infection, future research on
deworming and HIV infection ought to focus on patients initiating
or already on ART.
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